NCT05725902View on ClinicalTrials.gov

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

December 8, 2025

Study Completion Date

February 26, 2026

Conditions
Sickle Cell Disease
Interventions
DRUG

Etavopivat

The study intervention is etavopivat (400 mg), administered orally and once daily (QD)

Trial Locations (1)

30342

Emory University Children's Healthcare of Atlanta, Atlanta

Sponsors
All Listed Sponsors
collaborator

Emory University

OTHER

lead

Forma Therapeutics, Inc.

INDUSTRY

NCT05725902 - Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease | Biotech Hunter | Biotech Hunter